Immix Biopharma (NASDAQ:IMMX) Announces Earnings Results

Immix Biopharma (NASDAQ:IMMX) posted its earnings results on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.09, Zacks reports.

Immix Biopharma Price Performance

Immix Biopharma stock traded down $0.02 during mid-day trading on Wednesday, reaching $1.83. 12,323 shares of the stock traded hands, compared to its average volume of 133,311. Immix Biopharma has a 12-month low of $1.26 and a 12-month high of $3.23. The business’s 50-day moving average is $1.86 and its 200-day moving average is $1.86. The stock has a market capitalization of $50.34 million, a PE ratio of -2.15 and a beta of 0.26.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a report on Monday, February 10th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.